As the diagnosis of HLH often includes non-specific clinical and laboratory findings, future studies including more useful biomarkers such as low NK cell activity, markedly elevated s-IL-2r and markedly elevated soluble CD163 may help to identify the existence of a COVID-19-associated HLH and may guide clinical trials using immunosuppressive therapy in these patients. This evidence concerns the gene CD163 and hemophagocytic syndrome.